Iguratimod (IGU), a selective cyclooxygenase-2 (COX-2) inhibitor [16], is in clinical use for treatment of rheumatoid arthritis (RA) with low risk of progressive multifocal leukoencephalopathy and other adverse effects. This evidence concerns the gene PTGS2 and progressive multifocal leukoencephalopathy.